Stock GRTS GRITSTONE BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Gritstone bio, Inc.

Equities

GRTS

US39868T1051

Market Closed - Nasdaq
Other stock markets
 04:00:05 2024-04-23 pm EDT 		5-day change 1st Jan Change
0.7457 USD +0.03% Intraday chart for Gritstone bio, Inc. -3.39% -63.45%
Apr. 15 Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform CI
Apr. 02 Top Midday Decliners MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
PR
Nature Medicine Publishes Interim Results from Gritstone bio's Phase 1/2 Study of 'Off-the-Shelf' Neoantigen Vaccine Platform
AQ
Nature Medicine Publishes Interim Results from Gritstone bio’s Phase 1/2 Study of “Off-the-Shelf” Neoantigen Vaccine Platform (SLATE)
AQ
Nature Medicine Publishes Interim Results from Gritstone Bio's Phase 1/2 Study of "Off-The-Shelf" Neoantigen Vaccine Platform
CI
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
PR
Gritstone bio to Participate in Upcoming Investor and Scientific Conferences
AQ
Gritstone bio Presents Improvements to EDGE™ Platform at AACR 2024
AQ
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
PR
Top Midday Decliners
MT
Gritstone bio Prices $32.5 Million Public Offering of Stock, Warrants
MT
Gritstone bio Announces Pricing of $32.5 Million Underwritten Public Offering
AQ
Gritstone Bio Discloses Preliminary Progression-Free Survival Data From Colorectal Cancer Vaccine Trial; Shares Fall
MT
Gritstone Bio Starts Public Offering; Shares Drop After-Hours
MT
Gritstone bio Announces Proposed Public Offering
AQ
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
AQ
Gritstone Bio, Inc. Announces Positive Preliminary Progression-Free Survival and Long-Term Circulating Tumor DNA Data from Phase 2/3 Study of its Personalized Cancer Vaccine, Granite, Granite, Granite
CI
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gritstone bio, Inc. - GRTS
PR
Earnings Flash (GRTS) GRITSTONE BIO Posts Q4 Revenue $16.3M
MT
Gritstone bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
AQ
Gritstone bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GRTS Stock
  4. News Gritstone bio, Inc.